SEC Comment Letter 0000000000-24-014313 to Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc.
Date: Dec. 30, 2024 · CIK: 0001857044 · Accession: 0000000000-24-014313
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284026
Letter
December 30, 2024 Jeffrey A. Meckler Chief Executive Officer Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 Re:Indaptus Therapeutics, Inc. Registration Statement on Form S-1 Filed December 23, 2024 File No. 333-284026 Dear Jeffrey A. Meckler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gary M. Emmanuel, Esq.
Show Raw Text
December 30, 2024
Jeffrey A. Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle, 15th Floor
New York, NY 10019
Re:Indaptus Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 23, 2024
File No. 333-284026
Dear Jeffrey A. Meckler:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary M. Emmanuel, Esq.